Abbott Labs

Johnson & Johnson

Corcept Therapeutics

Pfizer

Amgen

AbbVie

Merck

Eli Lilly

Bristol-Myers

Pacira Pharmaceuticals

Invesco Dynamic Pharmaceuticals ETF

PJP tracks an index of US pharmaceutical companies selected and weighted based on various factors using a quantitative methodology.

iShares U.S. Healthcare Providers ETF

VanEck Vectors Pharmaceutical ETF

Investors looking for equities suddenly have more than a few options to consider in this mini-market rally. Whether markets have really priced in Fed action or a possible recession already or not, investors should take a look at healthcare ETFs offering consistency in a strong year for health insurers and pharmaceutical firms.

3 ETFs for the Healthcare Sector's Highs

Virtus LifeSci Biotech Clinical Trials ETF

VanEck Vectors Biotech ETF

iShares Nasdaq Biotechnology ETF

iShares U.S. Pharmaceuticals ETF

iShares U.S. Medical Devices ETF

iShares U.S. Healthcare ETF

Invesco Dynamic Biotechnology & Genome ETF

Vanguard Health Care ETF

SPDR S&P Biotech ETF

Health Care Select Sector SPDR Fund

SPDR S&P Pharmaceuticals ETF

The recently enacted Inflation Reduction Act looks to rein in prescription drug prices and could impact the pharma industry's long-term financial performance. The legislation caps out-of-pocket costs for Medicare prescriptions at $2,000 per year, starting in 2025.

What The Inflation Reduction Act Means For Drug Prices

Loncar Cancer Immunotherapy ETF

Amplify Treatments Testing & Advancements ETF

Global X Genomics & Biotechnology ETF

Invesco Nasdaq Biotechnology ETF

iShares Evolved U.S. Innovative Healthcare ETF

Pharma and biotech ETFs are in great shape and are trading at a one-month high level.

Pharma & Biotech ETFs at One-Month High: Here's Why

First Trust Nasdaq Pharmaceuticals ETF 

Many industry bigwigs reported solid results with some beating on earnings or revenues or both.

Pharma ETFs in Focus Post Q1 Earnings

GlaxoSmithKline

Direxion Daily Pharmaceutical & Medical Bull 3X Shares

Sanofi

The pending separation of consumer care businesses by pharmaceutical companies is understandable and may offer investment opportunities.

Pharma In Transition: Context And Opportunities

Solid earnings failed to impress pharma ETFs over the past month due to a broad sell-off in the market.

Solid Q4 Earnings Fail to Impress Pharma ETFs

Pharmaceuticals companies, even the old, large-cap variety, are innovators in their own right. They have to be.

Big Pharma Innovation Outlook Looks Healthy

The S&P 500 Health Care Index is up 18% year-to-date, an admiral though not spectacular performance. While coronavirus vaccines remain a point of much discussion, pharmaceuticals stocks also fit the bill as solid though not spectacular.

Economics, Patents Critical for Pharmaceuticals Innovation, Equity Prices

The slew of Q3 results has led to smooth trading in pharma ETFs over the past month.

Wave of Solid Q3 Earnings Push Pharma ETFs Higher

The Invesco Dynamic Pharmaceuticals ETF (NYSEArca: PJP) is off 3.66% month-to-date, and the source of that lethargy is easy to spot: The drug price reform debate is once again gaining momentum, prompting investors to take a cautious approach to pharmaceuticals stocks. While the healthcare sector and pharmaceuticals stocks in particular have histories of being sensitive [.

Blue-Chip Pharmaceuticals Stocks Contend With Political Headwinds

The healthcare sector is getting its groove back, as a variety of exchange traded funds dedicated to the group are printing or residing near new highs. The Invesco Dynamic Pharmaceuticals ETF (NYSEArca: PJP) is part of that group and closed just 2% below its all-time high last Friday.

Looking for Healthier Healthcare Stocks?

Pharma ETFs Gain on Q2 Earnings

First Trust Health Care AlphaDEX Fund

Upbeat earnings, COVID-19-related sales, compelling valuation and lucrative dividend prospects are boosting pharma and healthcare ETFs.

Pharma & Healthcare ETFs at a One-Year High: Here's Why

Virtus LifeSci Biotech Products ETF

Principal Healthcare Innovators Index ETF

Direxion Daily Healthcare Bull 3x Shares

First Trust NYSE Arca Biotechnology Index Fund

Fidelity MSCI Health Care ETF

abrdn Healthcare Investors 

abrdn Life Sciences Investors 

Defiance Nasdaq Junior Biotechnology ETF

John Hancock Multifactor Healthcare ETF

Direxion Daily S&P Biotech Bear 3X Shares

Direxion Daily S&P Biotech Bull 3X Shares

Global X Longevity Thematic ETF

ProShares UltraShort Health Care

ProShares Ultra Health Care

Invesco S&P 500 Equal Weight Health Care ETF

Pacer BioThreat ETF

The first quarter of 2021 was challenging for the biotechnology industry, as the selloff in March represented a sharp reversal from record highs in February. While the sector has remained relatively resilient throughout the pandemic, we expect a full recovery in the latter half of this year, as operations that were disrupted return to normal.

Biotech Innovations Remain At Forefront

Just over one year after COVID-19 disrupted our lives, we are now getting to the point where multiple vaccine options are nearly ubiquitous for those in the United States. Per the CDC, as of April 12, 36% of the entire US population has received at least one vaccine, and 79% of those aged 65 years and older.

Moving Beyond COVID In Biopharma

LeMaitre Vascular

The advantage for dividend investors in this sector is the wide choice of large and well-established companies. AbbVie is a drug company with strong exposure to the immunology and the oncology markets.

Healthcare: A Wide Choice Of Large And Well-Established Companies

Healthcare Q4 results seem robust given that it is the fourth-best sector from a revenue growth look and the sixth-strongest in terms of earnings growth.

Pharma ETFs in Focus Post Q4 Earnings

iShares Global Clean Energy ETF

iShares US Infrastructure ETF

iShares Core S&P Total U.S. Stock Market ETF

SPDR S&P Regional Banking ETF

Invesco Dynamic Building & Construction ETF

Invesco Solar ETF

Stocks came crashing on the first day of the New Year in apprehension of the outcome of the Georgia run-off elections.

ETFs to Watch Ahead of Georgia Senate Runoff

AstraZeneca has agreed to buy rare-disease specialist Alexion Pharmaceuticals for $39 billion. The deal would represent the biggest transaction in pharmaceuticals since 2019.

ETFs to Tap AstraZeneca Mega-Deal to Buy Alexion

Invesco S&P SmallCap Health Care ETF

SPDR S&P Health Care Services ETF

The broader medical sector should be in the spotlight now on hopes of a coronavirus vaccine and the likelihood of a divided congress.

3 Reasons to Bet on Healthcare ETFs

US Global Jets ETF

IQ US Real Estate Small Cap ETF

Invesco S&P 500 Equal Weight Energy ETF

News that a Pfizer and BioNTech vaccine candidate was more than 90% effective in avoiding COVID-19 in its clinical trial has instilled more optimism in the markets.

Vaccine Hopes & Divided Government: Sector ETFs to Win

Easing worries regarding major policy changes are driving the relief rally in the healthcare and biotech spaces in the post-election period.

Here's Why Healthcare ETFs Are Rallying Post Elections

The slew of Q3 results have led to mixed trading in pharma ETFs over the past month.

Q3 Earnings Fail to Impress Pharma ETFs

KraneShares MSCI All China Health Care Index ETF

The best pharmaceutical ETFs for Q4 2020 are KURE, XPH, and PJP.

Best Pharmaceutical ETFs for Q4 2020

Total earnings of 66.4% of the healthcare market capitalization that has reported so far are up 4.4% on revenue growth of 4%.

News for Invesco Dynamic Pharmaceuticals ETF ETF (PJP)